Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy
用于胰腺癌治疗的靶向基质穿透纳米颗粒药物的转化开发
基本信息
- 批准号:10705200
- 负责人:
- 金额:$ 84.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-19 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAdverse eventAwardBiochemicalBiodistributionBiological MarkersBiologyBiophysicsCancer BiologyCancer PatientCatalytic DomainClinicalClinical TrialsDevelopmentDoseDrug Delivery SystemsDrug KineticsDrug TargetingDrug resistanceDuct (organ) structureDuctal CarcinomaEndotoxinsEngineeringEvaluationFutureGene ExpressionGene Expression ProfileGenerationsGeneticGoalsGood Manufacturing ProcessHistologicHumanHyaluronic AcidIn VitroIndustrializationInvestigational DrugsInvestigational New Drug ApplicationJointsLeadLigandsMMP14 geneMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of pancreasMethodsMonitorMusNamesNanotechnologyOutcomePathologicPatientsPenetrationPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePhasePhase I Clinical TrialsProceduresProductionPropertyProtocols documentationQuality ControlRecombinantsRecommendationResearchResearch Project GrantsResistanceRodentScheduleSmall Business Innovation Research GrantStructureSystemSystemic TherapyTherapeuticTherapeutic AgentsTherapeutic EffectToxic effectTranslation ProcessTranslational ResearchTreatment EfficacyTumor BiologyUnresectableUrokinase Plasminogen Activator Receptoradvanced pancreatic cancercancer cellcancer survivalcancer therapycancer typechemotherapyclinical translationdensitydesigndrug developmentfirst-in-humangood laboratory practiceimprovedin vivoinnovationirinotecanlarge scale productionlead candidatemigrationmouse modelnanodrugnanoformulationnanoparticlenanoparticle drugnanotherapeuticneoplastic cellnovelnovel strategiespancreatic PDX modelspancreatic cancer cellspancreatic cancer patientspatient derived xenograft modelphase 1 studyphase 2 studypre-clinicalpreclinical evaluationpreclinical studyprogramsreceptor bindingstandard caresystemic toxicitytargeted deliverytargeted therapy trialstargeted treatmenttherapy resistanttreatment responsetumortumor growthtumor xenograft
项目摘要
Project Summary
Low efficiency in drug delivery and aggressive tumor biology are the major causes of resistance to therapy in
pancreatic cancer. The presence of a dense fibrous tumor stroma creates a drug delivery barrier and promotes
aggressive biology and drug resistance in pancreatic cancer cells. We have developed a targeted stroma
penetrating hyaluronic acid nanoparticle carrying SN38, an active metabolite of irinotecan. Results of preclinical
studies demonstrated significantly enhanced nanoparticle/drug delivery into ductal carcinoma cells to produce
strong therapeutic effects in drug resistant pancreatic cancer patient derived xenograft (PDX) models.
Importantly, the stroma-penetrating nanodrug has unique properties to modulate tumor stroma that allows the
nanodrug to pass through the stromal barrier but retain a protective stromal structure. For clinical translation of
this novel nanodrug, our SBIR phase I study focused on the re-engineering a tagless stroma penetrating ligand,
ATFmmp14 (R2), that consists of a urokinase plasminogen activator receptor (uPAR) binding domain and a
catalytic domain of MMP14, following the recommendation of the FDA Pre-IND team. We have developed the
tagless ATFmmp14(R2) with the capacity of large scale production in an endotoxin-free bacterial expressing
system. We also demonstrated that ATFmmp14 (R2) conjugated HANP/SN38 has comparable tumor targeting
ability and therapeutic efficacy to the first generation of His-tagged ATFmmp14(R1)-HANP/SN38 in pancreatic
cancer PDX models. The proposed phase II project aims to accelerate the translational process by conducting
important Investigational New Drug (IND)-enabling preclinical studies. In Aim 1, we will optimize and finalize
nanoformulation of MIGRA-NP01 for large-scale production under GLP/GMP conditions. We will then
characterize in vitro and in vivo properties of MIGRA-NP01, including biophysical and biochemical parameters
in vitro, and systemic toxicity, pharmacokinetics/pharmacodynamics, biodistribution, and clearance in normal
and tumor bearing mice (Aim 2). During those studies, we will establish the Stand Operating Protocols (SOPs)
and metrics for quality control (QC) of MIGRA-NP01 for drug development (Aim 2). Next, we will determine an
optimized dose and schedule for MIGRA-NP01 in pancreatic PDX models with different pathological and genetic
features, and sensitivity to chemotherapy (Aim 3). Finally, therapeutic responses of pancreatic PDX tumors will
be correlated with the gene expression signatures to identify the potential predicative biomarkers for MIGRA-
NP01 treatment (Aim 3). The outcomes of this translational research project include: 1) obtaining the final
optimized nanoformulation of MIGRA-NP01 with established SOPs for the GLP/GMP production of MIGRA-NP01
and producing two lots of the GLP grades of MIGRA-NP01; and 2) determining systemic toxicity, biodistribution,
therapeutic dose/schedule of the MIGRA-NP01 in normal mice and pancreatic PDX tumor bearing mice. Results
of the SBIR phase II project should have a great impact on the future submission of an IND application for the
FDA approval of a phase 1 clinical trial in advanced pancreatic cancer patients.
项目摘要
药物递送的低效率和侵袭性肿瘤生物学是肿瘤细胞对治疗耐药的主要原因。
胰腺癌致密的纤维性肿瘤间质的存在产生了药物递送屏障,并促进了肿瘤的生长。
胰腺癌细胞的侵袭性生物学和耐药性。我们开发了一种靶向基质
携带伊立替康活性代谢物SN 38的透明质酸纳米粒。临床前结果
研究表明,显著增强的纳米颗粒/药物递送到导管癌细胞中,
在耐药胰腺癌患者来源的异种移植物(PDX)模型中具有强的治疗效果。
重要的是,基质穿透纳米药物具有调节肿瘤基质的独特性质,
纳米药物可以穿过基质屏障,但保留保护性基质结构。用于临床翻译
对于这种新的纳米药物,我们的SBIR I期研究集中在重新设计无标签的基质穿透配体,
ATFmmp 14(R2),其由尿激酶纤溶酶原激活物受体(uPAR)结合结构域和
MMP 14的催化结构域,遵循FDA Pre-IND团队的建议。我们开发了
具有在无内毒素细菌中大规模生产能力的无标签ATFmmp 14(R2)表达载体,
系统我们还证明了ATFmmp 14(R2)缀合的HANP/SN 38具有相当的肿瘤靶向性,
第一代His标记的ATFmmp 14(R1)-HANP/SN 38在胰腺癌中的能力和治疗功效
癌症PDX模型。拟议的第二阶段项目旨在通过开展
重要的研究性新药(IND)-使临床前研究。在目标1中,我们将优化并最终确定
MIGRA-NP 01纳米制剂用于GLP/GMP条件下的大规模生产。然后我们将
表征MIGRA-NP 01的体外和体内特性,包括生物物理和生物化学参数
体外和全身毒性、药代动力学/药效学、生物分布和正常
和荷瘤小鼠(目的2)。在这些研究期间,我们将制定展台操作规程(SOP)
和MIGRA-NP 01用于药物开发的质量控制(QC)指标(目标2)。接下来,我们将确定一个
MIGRA-NP 01在具有不同病理和遗传的胰腺PDX模型中的优化剂量和方案
特征和对化疗的敏感性(目的3)。最后,胰腺PDX肿瘤的治疗反应将
与基因表达特征相关,以鉴定MIGRA的潜在预测性生物标志物-
NP 01治疗(目标3)。该转化研究项目的成果包括:1)获得最终的
MIGRA-NP 01的优化纳米制剂,具有MIGRA-NP 01的GLP/GMP生产的既定SOP
并生产两批GLP等级的MIGRA-NP 01;和2)测定全身毒性,生物分布,
图10示出了MIGRA-NP 01在正常小鼠和胰腺PDX荷瘤小鼠中的治疗剂量/时间表。结果
SBIR第二阶段项目的实施将对未来提交IND申请产生重大影响,
FDA批准在晚期胰腺癌患者中进行1期临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lily Yang其他文献
Lily Yang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lily Yang', 18)}}的其他基金
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
开发多功能药物和免疫调节剂递送纳米粒子,用于治疗患有动脉粥样硬化的癌症患者
- 批准号:
10548149 - 财政年份:2021
- 资助金额:
$ 84.19万 - 项目类别:
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
开发多功能药物和免疫调节剂递送纳米粒子,用于治疗患有动脉粥样硬化的癌症患者
- 批准号:
10334547 - 财政年份:2021
- 资助金额:
$ 84.19万 - 项目类别:
Translational Development of a Targeted and Stroma-breaking Nanoparticle Drug for Pancreatic Cancer Therapy
用于胰腺癌治疗的靶向和基质破坏纳米颗粒药物的转化开发
- 批准号:
9907528 - 财政年份:2019
- 资助金额:
$ 84.19万 - 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
- 批准号:
8700565 - 财政年份:2013
- 资助金额:
$ 84.19万 - 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
- 批准号:
8333962 - 财政年份:2011
- 资助金额:
$ 84.19万 - 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
- 批准号:
8518266 - 财政年份:2011
- 资助金额:
$ 84.19万 - 项目类别:
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
使用治疗诊断纳米颗粒靶向治疗三阴性乳腺癌
- 批准号:
8874343 - 财政年份:2011
- 资助金额:
$ 84.19万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 84.19万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 84.19万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 84.19万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 84.19万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 84.19万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 84.19万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 84.19万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 84.19万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 84.19万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 84.19万 - 项目类别: